cb-10-01
Cell therapyexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2007 (NCT00925314)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cb-10-01
- tli
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00925314 | Phase 2 | Jun 1, 2007 | Cosmo Pharmaceuticals, University of California, San Diego |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cosmo Pharmaceuticals | For profit | 1 | 1 | 1 | 2007 |
| University of California, San Diego | Academic/Hospital | 1 | 0 | 1 | 2007 |
2 organizations
Page 1 / 1